KZIA has been in the news 900% more than usual
Jul 12, 2024, 6:32 PM
-54.38%
What does KZIA do
Kazia Therapeutics Ltd, based in Sydney, Australia, specializes in oncology drug development with key projects including Paxalisib for brain cancer and EVT801 targeting VEGFR3 in various cancers. The company focuses on pharmaceutical research and development, addressing critical pathways in cancer cell growth and metastasis.
KZIA has been in the news recently: Kazia Therapeutics (KZIA) stock increased on Thursday due to positive momentum from a press release suggesting potential growth. Meanwhile, Conagra Brands, Inc. saw a decrease in shares following lower-than-expected fourth-quarter sales and below-estimate FY25 adjusted EPS guidance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.